416 related articles for article (PubMed ID: 33037044)
21. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
[TBL] [Abstract][Full Text] [Related]
22. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.
Mitra P; Kasliwala R; Iboki L; Madari S; Williams Z; Takahashi R; Taub ME
Pharm Res; 2023 Dec; 40(12):3025-3042. PubMed ID: 37821766
[TBL] [Abstract][Full Text] [Related]
24. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
[TBL] [Abstract][Full Text] [Related]
25. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
26. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
29. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
[TBL] [Abstract][Full Text] [Related]
31. Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes.
Izumi S; Nozaki Y; Kusuhara H; Hotta K; Mochizuki T; Komori T; Maeda K; Sugiyama Y
Mol Pharm; 2018 Jun; 15(6):2277-2288. PubMed ID: 29746136
[TBL] [Abstract][Full Text] [Related]
32. Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.
Chen Y; Ma F; Jones NS; Yoshida K; Chiang PC; Durk MR; Wright MR; Jin JY; Chinn LW
CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):332-341. PubMed ID: 32383787
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
35. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
[TBL] [Abstract][Full Text] [Related]
36. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.
Jones NS; Yoshida K; Salphati L; Kenny JR; Durk MR; Chinn LW
Clin Pharmacol Ther; 2020 Jan; 107(1):269-277. PubMed ID: 31376152
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
[TBL] [Abstract][Full Text] [Related]
38. Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.
Dong J; Olaleye OE; Jiang R; Li J; Lu C; Du F; Xu F; Yang J; Wang F; Jia W; Li C
Br J Pharmacol; 2018 Sep; 175(17):3486-3503. PubMed ID: 29908072
[TBL] [Abstract][Full Text] [Related]
39. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
40. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
Takubo H; Bessho K; Watari R; Shigemi R
Xenobiotica; 2022 Apr; 52(4):397-404. PubMed ID: 35638858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
